Korro Bio vs Ovid Therapeutics
KRRO and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRRO and OVID compare
Ovid Therapeutics is the larger company, worth 2.4 times as much as Korro Bio ($498M against $211M).
Ovid Therapeutics grew revenue faster over the last twelve months (−78.0% versus −82.5% for Korro Bio).
Ovid Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2971% compared with −8214% at Korro Bio.
Ovid Therapeutics scores higher on the StockData Score (9 against 5 for Korro Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRRO | OVID |
|---|---|---|
| Size and price | ||
| Market cap | $211M | $498M |
| Share price | $14.31 | $2.55 |
| Change, 1 year | −56.4% | 88.9% |
| Change, 5 years | −95.2% | −25.9% |
| Beta (5Y) | 2.09 | 1.21 |
| Employees | 58 | 23 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 163× (better) | 343× |
| P/B | – | 2.5× |
| FCF yield | −30.3% | – |
| Growth | ||
| Revenue growth (TTM) | −82.5% | −78.0% (better) |
| Revenue growth, 5Y average | −29.6% | −10.5% (better) |
| Profitability | ||
| Operating margin | −8467% | −4700% (better) |
| Net margin | −8214% | −2971% (better) |
| FCF margin | −4944% | – |
| Return on equity | – | −35.4% |
| Return on invested capital | – | −191% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 7.30 | 11.97 (better) |
| Altman Z-score | −3.71 | 10.01 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 75.3% |
| Held by insiders | 27.5% | 13.6% |
| Insider net buying, 12 months | $16.0M (better) | −$29.3K |
| Short interest, % of float | 16.4% | 10.8% |
Go deeper
- KRRO stock overview
- KRRO income statement
- KRRO valuation and score
- OVID stock overview
- OVID income statement
- OVID valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.